Shingrix is a recombinant adjuvant subunit vaccine. The vaccine is approved in 
Germany for prevention of zoster manifestation and postherpetic neuralgia in 
adults aged ≥60 years. In the case of bullous skin lesions after vaccination 
with Shingrix a zoster disease should be considered. Unexpected side effects 
associated with the vaccination should be reported to the Drug Commission of the 
German Medical Association.